CCEL

Cryo-Cell International, Inc. - 10-Q Summary

Business Context and Reporting Period

Cryo-Cell International, Inc. is engaged in cellular processing and cryogenic storage, primarily focusing on umbilical cord blood stem cells (U-Cord) and menstrual stem cells (C'elle). This report covers the quarterly period ended February 28, 2009. The company operates as a smaller reporting company with no indebtedness as of the filing date.

Key Financial Metrics

Material Changes vs. Prior Period

• Profitability Turnaround: The company reported a net income of $535,686 ($0.05 per share) compared to a net loss of $247,258 ($0.02 per share) in the prior year. This shift was driven by significant expense reductions.
• Revenue Decline: Total revenue decreased by 7% to $3.86 million. This was primarily due to a 9% decrease in specimens processed and a 17% increase in sales discounts, partially offset by a 9% increase in recurring storage fees.
• Expense Reductions:
  • Marketing, General & Administrative expenses dropped 23% to $2.10 million due to improved operational efficiencies and reduced strategic spending.
  • Cost of sales decreased 23% to $1.11 million, reflecting fewer specimens processed.
  • Research and Development expenses fell 43% to $25,640, as the initial commercialization costs for the C'elle technology in 2008 were not repeated.
• Liquidity Improvement: Cash and cash equivalents increased by approximately $992,000 during the quarter, driven by positive operating cash flow and collections on accounts receivable.

Outlook, Risks, and Contingencies

• Liquidity Outlook: Management anticipates that current cash, marketable securities, and operating cash flows will be sufficient to fund known needs for at least the next 12 months. Non-discretionary capital expenditures are estimated at $250,000 over the next year.
• Revenue Sharing Agreements (RSAs): The company has long-term RSAs covering New York, Texas, Florida, and Illinois. Interest expense related to these agreements was $324,241 for the quarter. Payments fluctuate based on storage revenue in these regions.
• Legal Proceedings: The company is involved in patent litigation with PharmaStem Therapeutics, Inc. The U.S. Court of Appeals for the Federal Circuit previously ruled in Cryo-Cell's favor regarding two patents, a decision made final by the Supreme Court's denial of certiorari. A second case involving two other patents is expected to be dismissed after the U.S. PTO cancelled all claims of those patents in September 2008.
• Warranty Reserves: The company maintains a reserve of approximately $111,000 for its product warranty and Cryo-Cell Cares program. No claims have been experienced to date, but reserves are based on estimated usage and failure rates which could change.
• Investment in Affiliate: The company holds a 36% interest in Saneron CCEL Therapeutics, Inc., recorded at $684,000. The company recorded equity in losses of $31,867 for the quarter related to stock compensation at the affiliate.

Investor Verification Checklist

• Verify the sustainability of the 23% reduction in marketing and administrative expenses and whether this impacts future growth.
• Monitor the 9% decline in specimens processed to assess demand trends for cord blood storage.
• Review the status of the second PharmaStem litigation case to confirm dismissal following the PTO patent cancellations.
• Assess the impact of the $3.75 million long-term liability for revenue sharing agreements on future cash flows.
• Confirm the collectability of accounts receivable, noting the allowance for doubtful accounts increased to $844,630.